http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전복환,박호선,최윤,황규계,우규진,정현용,박증석,박송용 대한바이러스학회 1995 Journal of Bacteriology and Virology Vol.25 No.1
A human embryonic lung fibroblast (LuMA) cell line has been established for production of a live attenuated varicella vaccine. We have investigated the possibility of using serum-free medium for growth of LuMA cells and propagation of both cell-associated and cell-free varicella- zoster virus (VZV). The medium was supplemented with serum-free supplements (HITE: human serum albumin, insulin, transferrin, and monoethanolamine) in a mixture of basal serum-free medium (a mixture of DME and Ham's F12 medium, 1: 1). We have also investigated the effects of lipid supplementation and low serum addition for promotion of virus propagation in serum-free medium supplemented with HITE. Although the serum-free medium was not adequate for LuMA cell growth, the medium supplemented with concentrated lipid emulsion (CLE) was comparable to DME medium supplemented with 2% fetal bovine serum (FBS) in respect of VZV propagation.
Microcarrier를 이용한 사람 폐세포에서 수두 바이러스의 증식
전복환,박손용,문홍모 대한바이러스학회 1994 Journal of Bacteriology and Virology Vol.24 No.1
A human embryonic lung fibroblast(LuMA) cell line was established for production of a live attenuated varicella-zoster virus vaccine. Using this cell line, we have investigated the possibili ty of using microcarrier culture system for producing cell-associated and cell-free varicellazoster virus. We have also investigated the utilization of glucose and amino acids during cell culture and virus propagation in microcarrier culture. It was found that no infectious cell-free viruses appear in the culture medium, and substantial decreases in cell density was observed a cell culture time increase. The cell-free varicella-zoster virus yield in microcarrier culture was much lower than that of the stationary T-flask culture.
Microcarrier 배양에서 세포부착과 바이러스 역가변화에 미치는 바이러스 감염 비율의 영향
전복환,박호선,우규진,황규계,박송용,문홍모 대한바이러스학회 1995 Journal of Bacteriology and Virology Vol.25 No.2
We had previously evaluated the possibility of using microcarrier culture system to produce attenuated cell-associated and cell-free varicella-zoster virus (VZV). We have investigated the attachment characteristics of both normal human embryonic lung (LuMA) cells and virus-infected LuMA cells on cell-grown microcarriers with various multiplicities of infection. In cell at tachment period for virus infection, a portion of the unattached normal cells in culture medium was increased with the decrease of unattached VZV-infected cells regardless of infection ratio. VZV yield was enhanced with increase of initial virus-infected cells onto cell-laden microcarriers. By understanding relationship between the attachment kinetics of cells and virus titers and by determining virus infection ratio, it might be possible to propagate the VZV efficiently using mi- crocarrier culture system.
C-42 : A New Commercial Scale Cell Culture Manufacturing Facility In Korea
전복환,셀트리온 한국화학공학회 2007 화학공학의이론과응용 Vol.10 No.2
The mammalian cell culture technique is one of the most important biotherapeutic production techniques which are in high demand recently. Celltrion Inc is constructing a state-of-theart commercial cell culture bulk pharmaceutical cGMP facility on a 92,500 square meter in Incheon, South Korea. Manufacturing suite in Incheon consists of four 12,500 L production bioreactors. These facilities will be mechanically completed in Dec. 2004, and will be validated in cGMP compliance by mid-2005. The facility is used to manufacture therapeutic recombinant proteins and Mabs designed to meet US FDA as well as EU standards. Celltrion provides a complete development package, taking a product from vector construction and cell line development through to full-scale manufacture, including a full range of analytical services and regulatory support for clinical trials and in market supply through a fully integrated cGMP manufacturing services for the biotechnology and biopharmaceutical industries utilizing mammalian cell culture to support pre-clinical, clinical phase and commercial production. Celltrion can offer the advantages of lower cost structure, the assurance of intellectual property protection, and high-quality, U.S.-based technology transfer for process development and manufacturing.